Pharmacokinetic Variability in Anti‐TFPI Therapies: Why Absolute Metrics Matter for Plasma Monitoring

Manuel Rodríguez López has participated in Advisory Boards for Amgen, CSL Behring, Rovi, Sobi, Novo Nordisk, and Octapharma; and as speaker for Pfizer, CSL Behring, Sobi, Octapharma, Novo Nordisk, and Amgen. Maria Teresa Alvarez Roman has participated in Advisory Boards for Amgen, Pfizer, CSL Behring, Rovi, Sobi, Novo Nordisk, Takeda, and Octapharma; and as speaker for Pfizer, CSL Behring, Sobi, Octapharma, Novo Nordisk, Amgen, and Takeda. Michael Calviño Suarez has participated in Advisory Boards for Amgen, Rovi, Sobi, and Novo Nordisk; and as speaker for Sobi, Novo Nordisk, Amgen, and Rovi. Ramiro Núñez Vázquez has participated in Advisory Boards for Amgen, Pfizer, CSL Behring, Rovi, Sobi, Novo Nordisk, Takeda, and Octapharma; and as speaker for Pfizer, CSL Behring, Sobi, Octapharma, Novo Nordisk, Amgen, and Takeda. Carmen Albo López declares no conflicts of interest. Data Availability Statement: All data relevant to this correspondence are included in the manuscript and cited references.